Economic impact of HIV in the highly active antiretroviral therapy Era - Reflections looking forward

AIDS Reviews

Volumn 20, Issue 4, 2018, Pages 226-235

  Oliva Moreno, Juan ^a   Trapero Bertran, Marta ^b  

^a UNIVERSITY OF CASTILLA LA MANCHA   (Spain)

^b UNIVERSITAT INTERNACIONAL DE CATALUNYA   (Spain)

Author keywords

Aging; Comorbidity; Economic impact; Health care cost; HIV; Labor force participation rate

Indexed keywords

ANTIRETROVIRUS AGENT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; AGING; ARTICLE; BUDGET; COMORBIDITY; HEALTH CARE COST; HEALTH CARE SYSTEM; HIGH INCOME COUNTRY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN IMMUNODEFICIENCY VIRUS PREVALENCE; LIFE EXPECTANCY; PUBLIC HEALTH; PUBLIC HEALTH PROBLEM; RETIREMENT; WORKFORCE; COST OF ILLNESS; ECONOMICS; PREVALENCE; PROCEDURES;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; COST OF ILLNESS; HEALTH CARE COSTS; HIV INFECTIONS; HUMANS; PREVALENCE;

EID: 85058745801     PISSN: 11396121     EISSN: None     Source Type: Journal    
DOI: 10.24875/AIDSRev.M17000011     Document Type: Article

References (78)

1. Fauci AS. The AIDS epidemic-considerations for the 21st century. N Engl J Med. 1999;341:1046-50.
2. European Centre for Disease Prevention and Control. The Status of the HIV Response in the European Union/European Economic Area, 2016. Stockholm: ECDC; 2017.
3. GBD DALYs and HALE Collaborators. Global, regional, and national disability-adjusted life-years (DALYs) for 315 diseases and injuries and healthy life expectancy (HALE), 1990-2015: A systematic analysis for the Global Burden of Disease Study 2015. Lancet. 2016;388:1603-58.
4. Global AIDS Response Progress Reporting (GARPR). Construction of Core Indicators for Monitoring the 2011 United Nations Political Declaration on HIV and AIDS. UP Date 2016. UNAIDS 2016 Estimates. Geneva, Switzerland: GARPR.
5. Bhaskaran K, Hamouda O, Sannes M, et al. Changes in the risk of death after HIV seroconversion compared with mortality in the general population. JAMA. 2008;300:51-9.
6. Antiretroviral Therapy Cohort Collaboration. Life expectancy of individuals on combination antiretroviral therapy in high-income countries: A collaborative analysis of 14 cohort studies. Lancet. 2008;372:293-9.
7. Bedimo RJ, McGinnis KA, Dunlap M, Rodriguez-Barradas MC, Justice AC. Incidence of non-AIDS-defining malignancies in HIV-infected versus noninfected patients in the HAART era: Impact of immunosuppression. J Acquir Immune Defic Syndr. 2009;52:203-8.
8. Silverberg MJ, Chao C, Leyden WA, et al. HIV infection and the risk of cancers with and without a known infectious cause. AIDS. 2009;23:2337-45.
9. Weber R, Sabin CA, Friis-Møller N, et al. Liver-related deaths in persons infected with the human immunodeficiency virus: The D:A:D study. Arch Intern Med. 2006;166:1632-41.
10. Islam FM, Wu J, Jansson J, Wilson DP. Relative risk of renal disease among people living with HIV: A systematic review and meta-analysis. BMC Public Health. 2012;12:234.
11. Klein D, Hurley LB, Quesenberry CP Jr, Sidney S. Do protease inhibitors increase the risk for coronary heart disease in patients with HIV-1 infection? J Acquir Immune Defic Syndr. 2002;30:471-7.
12. Currier JS, Taylor A, Boyd F, et al. Coronary heart disease in HIV-infected individuals. J Acquir Immune Defic Syndr. 2003;33:506-12.
13. Mary-Krause M, Cotte L, Simon A, et al. Increased risk of myocardial infarction with duration of protease inhibitor therapy in HIV-infected men. AIDS. 2003;17:2479-86.
14. Heaton RK, Franklin DR, Ellis RJ, et al. HIV-associated neurocognitive disorders before and during the era of combination antiretroviral therapy: Differences in rates, nature, and predictors. J Neurovirol. 2011;17:3-16.
15. Antiretroviral Therapy Cohort Collaboration. Causes of death in HIV-1-infected patients treated with antiretroviral therapy, 1996-2006: Collaborative analysis of 13 HIV cohort studies. Clin Infect Dis. 2010;50:1387-96.
16. Libman H. Will you still treat me when i’m 64? Care of the older adult with HIV infection. Top Antivir Med. 2015;23:97-103.
17. Smit M, Brinkman K, Geerlings S, et al. Future challenges for clinical care of an ageing population infected with HIV: A modelling study. Lancet Infect Dis. 2015;15:810-8.
18. Smit M, Cassidy R, Cozzi-Lepri A, et al. Quantifying the future clinical burden of an ageing HIV positive population in Italy: A mathematical modelling study. J Int AIDS Soc. 2016;19 Suppl 7:P156.
19. Nguyen N, Holodniy M. HIV infection in the elderly. Clin Interv Aging. 2008;3:453-72.
20. Desai S, Landay A. Early immune senescence in HIV disease. Curr HIV/AIDS Rep. 2010;7:4-10.
21. Pathai S, Bajillan H, Landay AL, High KP. Is HIV a model of accelerated or accentuated aging? J Gerontol A Biol Sci Med Sci. 2014;69:833-42.
22. Fried LP, Tangen CM, Walston J, et al. Frailty in older adults: Evidence for a phenotype. J Gerontol A Biol Sci Med Sci. 2001;56:M146-56.
23. García-Nogueras I, Aranda-Reneo I, Peña-Longobardo LM, Oliva-Moreno J, Abizanda P. Use of health resources and healthcare costs associated with frailty: The FRADEA study. J Nutr Health Aging. 2017;21:207-14.
24. Saves M, Chene G, Ducimetiere P, et al. Risk factors for coronary heart disease in patients treated for HIV infection compared with the general population. Clin Infect Dis. 2003;37:292-8.
25. Grinspoon SK. Metabolic syndrome and cardiovascular disease in patients with human immunodeficiency virus. Am J Med. 2005;118 Suppl 2:23S-28.
26. Hernando V, Alejos B, Monge S, et al. All-cause mortality in the cohorts of the Spanish AIDS research network (RIS) compared with the general population: 1997-2010. BMC Infect Dis. 2013;13:382.
27. Marcus JL, Chao CR, Leyden WA, et al. Narrowing the gap in life expectancy between HIV-infected and HIV-uninfected individuals with access to care. J Acquir Immune Defic Syndr. 2016;73:39-46.
28. Paraskevis D, Nikolopoulos G, Fotiou A, et al. Economic recession and emergence of an HIV-1 outbreak among drug injectors in Athens metropolitan area: A longitudinal study. PLoS One. 2013;8:e78941.
29. Soriano V, Barreiro P. Healthcare resources restrictions and human immunodeficiency virus infection. Med Clin (Barc). 2013;141:114-5.
30. Nakagawa F, Miners A, Smith CJ, et al. Projected lifetime healthcare costs associated with HIV infection. PLoS One. 2015;10:e0125018.
31. Hellinger FJ. Economic models of antiretroviral therapy: Searching for the optimal strategy. Pharmacoeconomics. 2006;24:631-42.
32. Levy AR, James D, Johnston KM, et al. The direct costs of HIV/AIDS care. Lancet Infect Dis. 2006;6:171-7.
33. Hellinger FJ. The lifetime cost of treating a person with HIV. JAMA. 1993;270:474-8.
34. Stoll M, Claes C, Schulte E, Graf von der Schulenburg JM, Schmidt RE. Direct costs for the treatment of HIV-infection in a German cohort after the introduction of HAART. Eur J Med Res. 2002;7:463-71.
35. Tramarin A, Campostrini S, Postma MJ, et al. A multicentre study of patient survival, disability, quality of life and cost of care: Among patients with AIDS in northern Italy. Pharmacoeconomics. 2004;22:43-53.
36. Merito M, Bonaccorsi A, Pammolli F, et al. Economic evaluation of HIV treatments: The I.CO.N.A. cohort study. Health Policy. 2005;74:304-13.
37. Krentz HB, Auld MC, Gill MJ; HIV Economic Study Group. The changing direct costs of medical care for patients with HIV/AIDS, 1995-2001. CMAJ. 2003;169:106-10.
38. Flori YA, le Vaillant M. Use and cost of antiretrovirals in France 1995- 2000: An analysis based on the medical dossier on human immunodeficiency (release 2) database. Pharmacoeconomics. 2004;22:1061-70.
39. Basuyau F, Josset V, Merle V, Czernichow P. Case fatality and health care costs in HIV-infected patients: Evolution from 1992 to 2000 at Rouen University Hospital, France. Int J STD AIDS. 2004;15:679-84.
40. Trapero-Bertran M, Oliva-Moreno J. Economic impact of HIV/AIDS: A systematic review in five European countries. Health Econ Rev. 2014;4:15.
41. Healthcare Cost and Utilization Project (HCUP) Statistical Briefs. Rockville (MD): Agency for Healthcare Research and Quality (US); 2006-.Source Heslin KC, Elixhauser A. Authors HIV Hospital Stays in the United States, 2006-2013: Statistical Brief #206.
42. Long LC, Fox MP, Sauls C, et al. The high cost of HIV-positive inpatient care at an Urban hospital in Johannesburg, South Africa. PLoS One. 2016;11:e0148546.
43. Nosyk B, Lima V, Colley G, Yip B, Hogg RS, Montaner JS. Costs of health resource utilization among HIV-positive individuals in British Columbia, Canada: Results from a population-level study. Pharmacoeconomics. 2015;33:243-53.
44. Owusu-Edusei K Jr, Gift TL, Patton ME, Johnson DB, Valentine JA. Estimating the total annual direct cost of providing sexually transmitted infection and HIV testing and counseling for men who have sex with men in the United States. Sex Transm Dis. 2015;42:586-9.
45. Perelman J, Alves J, Miranda AC, et al. Direct treatment costs of HIV/ AIDS in Portugal. Rev Saude Publica. 2013;47:865-72.
46. Schackman BR, Fleishman JA, Su AE, et al. The lifetime medical cost savings from preventing HIV in the United States. Med Care. 2015; 53:293-301.
47. Treskova M, Kuhlmann A, Bogner J, et al. Analysis of contemporary HIV/ AIDS health care costs in Germany: Driving factors and distribution across antiretroviral therapy lines. Medicine (Baltimore). 2016;95:e3961.
48. Carnevale RC, de Godoi Rezende Costa Molino C, Visacri MB, et al. Cost analysis of pharmaceutical care provided to HIV-infected patients: An ambispective controlled study. Daru. 2015;23:13.
49. Brennan A, Jackson A, Horgan M, Bergin CJ, Browne JP. Resource utilisation and cost of ambulatory HIV care in a regional HIV centre in Ireland: A micro-costing study. BMC Health Serv Res. 2015;15:139.
50. Krentz HB, Gill MJ. Increased costs of HIV care associated with aging in an HIV-infected population. HIV Med. 2015;16:38-47.
51. Gimeno-Gracia M, Crusells-Canales MJ, Guarc-Prades E, Rabanaque-Hernández MJ. Health care use among older male patients with HIV infection. Rev Clin Esp. 2017;217:304-6.
52. Guaraldi G, Zona S, Menozzi M, et al. Cost of non-infectious comorbidities in patients with HIV. Clin Econ Outcomes Res. 2013;5:481-8.
53. Quiros-Roldan E, Magoni M, Raffetti E, et al. The burden of chronic diseases and cost-of-care in subjects with HIV infection in a Health District of Northern Italy over a 12-year period compared to that of the general population. BMC Public Health. 2016;16:1146.
54. International Labour Organization. ILO Programme on HIV/AIDS and the World of Work: HIV/AIDS and Employment, ILO Governing Body 292nd Session; 2005.
55. Centro Nacional de Epidemiología-Instituto de Salud Carlos III/Plan Nacional sobre el Sida. Hospitalaria de Pacientes con VIH/SIDA. Available from: https://www.msssi.gob.es/ciudadanos/enfLesiones/enfTransmisibles/sida/vigilancia/home.htm.
56. Scitovsky AA, Rice DP. Estimates of the direct and indirect costs of acquired immunodeficiency syndrome in the United States, 1985, 1986, and 1991. J Med Pract Manage. 1988;3:234-41.
57. Yelin EH, Greenblatt RM, Hollander H, McMaster JR. The impact of HIVrelated illness on employment. Am J Public Health. 1991;81:79-84.
58. Massagli MP, Weissman JS, Seage GR 3rd, Epstein AM. Correlates of employment after AIDS diagnosis in the Boston Health Study. Am J Public Health. 1994;84:1976-81.
59. Leigh JP, Lubeck DP, Farnham P, Fries JF. Potential and actual workdays lost among patients with HIV. J Acquir Immune Defic Syndr Hum Retrovirol. 1995;8:392-8.
60. Laursen E, Larsen L. Socio-economic status of AIDS patients. Scand J Soc Med. 1995;23:189-92.
61. Dray-Spira R, Lert F, Marimoutou C, Bouhnik AD, Obadia Y. Socioeconomic conditions, health status and employment among persons living with HIV/AIDS in France in 2001. AIDS Care. 2003;15:739-48.
62. Rabkin JG, McElhiney M, Ferrando SJ, Van Gorp W, Lin SH. Predictors of employment of men with HIV/AIDS: A longitudinal study. Psychosom Med. 2004;66:72-8.
63. Goldman DP, Bao Y. Effective HIV treatment and the employment of HIV(+) adults. Health Serv Res. 2004;39:1691-712.
64. Bernell SL, Shinogle JA. The relationship between HAART use and employment for HIV-positive individuals: An empirical analysis and policy outlook. Health Policy. 2005;71:255-64.
65. Dray-Spira R, Legeai C, Le Den M, et al. Burden of HIV disease and comorbidities on the chances of maintaining employment in the era of sustained combined antiretoviral therapies use. AIDS. 2012;26:207-15.
66. Auld MC. Disentangling the effects of morbidity and life expectancy on labor market outcomes. Health Econ. 2002;11:471-83.
67. Oliva J. Labour participation of people living with HIV/AIDS in Spain. Health Econ. 2010;19:491-500.
68. Fogarty AS, Zablotska I, Rawstorne P, Prestage G, Kippax SC. Factors distinguishing employed from unemployed people in the Positive Health Study. AIDS. 2007;21 Suppl 1:S37-42.
69. Galárraga O, Salkever DS, Cook JA, Gange SJ. An instrumental variables evaluation of the effect of antidepressant use on employment among HIV-infected women using antiretroviral therapy in the United States: 1996-2004. Health Econ. 2010;19:173-88.
70. Rodger AJ, Brecker N, Bhagani S, et al. Attitudes and barriers to employment in HIV-positive patients. Occup Med (Lond). 2010;60:423-9.
71. Rueda S, Raboud J, Mustard C, Bayoumi A, Lavis JN, Rourke SB. Employment status is associated with both physical and mental health quality of life in people living with HIV. AIDS Care. 2011;23:435-43.
72. Sendi P, Brouwer WB, Bucher HC, Weber R, Battegay M; Swiss HIV Cohort Study. When time is more than money: The allocation of time between work and leisure in HIV-infected patients. Soc Sci Med. 2007;64:2355-61.
73. Elzi L, Conen A, Patzen A, et al. Ability to work and employment rates in human immunodeficiency virus (HIV)-1-infected individuals receiving combination antiretroviral therapy: The swiss HIV cohort study. Open Forum Infect Dis. 2016;3:ofw022.
74. Wagener MN, van den Dries L, Van Exel J, et al. Determinants of employment in people living with HIV in the Netherlands. J Occup Rehabil. 2017.
75. Annequin M, Lert F, Spire B, Dray-Spira R; and the ANRS-Vespa Study Group. Increase in unemployment over the 2000’s: Comparison between people living with HIV and the french general population. PLoS One. 2016;11:e0165634.
76. Groß M, Herr A, Hower M, et al. Unemployment, health, and education of HIV-infected males in Germany. Int J Public Health. 2016;61:593-602.
77. Worthington C, O’Brien K, Zack E, et al. Enhancing labour force participation for people living with HIV: A multi-perspective summary of the research evidence. AIDS Behav. 2012;16:213-43.
78. Dray-Spira R, Lert F; VESPA Study Group. Living and working with HIV in France in 2003: Results from the ANRS-EN12-VESPA Study. AIDS. 2007;21 Suppl 1:S29-36.